The spring booster programme: now you need it, now you don’t 

On 1st February, the website Chemist And Druggist announced the launch of private covid jabs, under the headline UK’s first private pharmacy COVID-19 vaccine service launched today

This is a slight over-statement, in that supplies are not likely to come till April, but is nevertheless a warning of the direction of travel.  Over the next few days, several pharmacy groups made similar announcements.

Read More

Who does ‘our’ NHS really serve?

The fact that the NHS is wasting millions of taxpayer pounds continuing to promote these ineffective and harmful products is really symbolic of what the health service has become. Simply another cog in the medical industrial machine, whirring to improve Pharma profits with little or no concern for end user health. In a service allegedly crushed by lack of resources, why on earth are they still pushing these toxic products on an unsuspecting ‘vulnerable’ sector of society?

Read More

Three years on from the first covid vaccine death

3 years ago today, Dr Stephen Wright died from vaccine-induced thrombosis, caused by the AstraZeneca covid vaccine he received on 16th January 2021.

Like many others he was assured it was Safe and Effective and that he should take it to protect others.

His family mentioned the vaccine could be the cause when he was hospitalised and a Yellow Card was completed in early February 2021. MHRA took zero action on this 1st known death!

Read More

Open letter to the JCVI – 19th August 2021

Children do not need Covid vaccines Open letter to Joint Committee on Vaccination and Immunisation                                                                                                    19th August 2021 Dear Professor Lim and colleagues, As you know, a group of 60 British doctors and scientists wrote to the MHRA in May with a copy to members of the JCVI, expressing our concerns about the potential […]

Read More

Open letter to JCVI 9th December 2021

Why give a second dose to children? Professor Lim, Chairman, JCVI COVID-19 subcommittee Dr June Raine, Chief Executive, MHRA Rt Hon Sajid Javid, Secretary of State for Health and Social Care Professor Chris Whitty, Chief Medical Officer for England Sir Patrick Vallance, Government Chief Scientific Adviser Dr Jenny Harries, Chief Executive, UKHSA 9th December 2021 […]

Read More

Open letter to JCVI 6th June 2021

Professor Wei Shen Lim, Chairman, Covid-19 immunisation committee, Joint Committee on Vaccination and Immunisation (JCVI) Dear Professor Lim,  I and 50 senior doctors and academics, wrote to you urgently on 17th May (linked here) to express our grave concerns about the possibility of the COVID-19 vaccination programme being extended to children. I was informed that the letter […]

Read More

Pfizer sued… what about BioNTech?

As we wrote in the last HART bulletin’s Pick of the Week, we are encouraged that legal cases are starting to appear, even if ‘victories’ have been few and far between. We should certainly be wary of getting our hopes up and being fooled by ‘dead cat’ distractions. After all, what are the perpetrators of this fiasco up to while we are fed the latest distraction?

Read More

Another measure of the vaccines’ evident failure is being flagrantly ignored

Before Public Health England became UKHSA they devised a way of measuring the proportion of household contacts who were ill a few days later – the secondary attack rate. Many publications on secondary attack rates claim very high percentages but fail to exclude people within a household who became ill at the same time as each other and should both be considered primary cases. Public Health England did exclude these situations and found very consistent results as a consequence.

Read More

Were covid vaccine trials misleading by design?

The covid vaccine trials did not focus on how many were healthy instead comparing those who developed disease. To take the Pfizer/BioNTech trial as an example, there were 8 PCR positive symptomatic people in the vaccine group and 162 in the placebo group more than a week after the second dose and after up to 2 month’s follow up. That worked out at a 94.6% efficacy when calculated as a percentage reduction.

Read More